The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin-Induced Nephrotoxicity
Open accessAbstract
Cisplatin is one of the most widely used anticancer agents for the treatment of solid tumors. The clinical use of cisplatin is associated with dose-limiting nephrotoxicity, which occurs in one-third of patients despite intensive prophylactic measures. Organic cation transporter 2 (OCT2) has been implicated in the cellular uptake of cisplatin, but its role in cisplatin-induced nephrotoxicity remains unknown. In mice, deletion of Oct1 and Oct2 resulted in significantly impaired urinary excretion of cisplatin without an apparent influence on plasma levels. Furthermore, the Oct1/Oct2-deficient mice were protected from severe cisplatin-induced renal tubular damage. Subsequently, we found that a nonsynonymous single-nucleotide polymorphism (SNP) in the OCT2 gene SLC22A2 (rs316019) was associated with reduced cisplatin-induced nephrotoxicity in patients. Collectively, these results indicate the critical importance of OCT2 in the renal handling and related renal toxicity of cisplatin and provide a rationale for the development of new targeted approaches to mitigate this debilitating side effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717
Platinum Compounds: a New Class of Potent Antitumour Agents
ROSENBERG, B., VANCAMP, L., TROSKO, J. E., & MANSOUR, V. H. (1969) · Nature · doi:10.1038/222385a0 · Cited by 3,972
Cellular processing of platinum anticancer drugs
Wang, D., & Lippard, S. J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1691 · Cited by 3,801
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
Jamieson, E. R., & Lippard, S. J. (1999) · Chemical Reviews · doi:10.1021/cr980421n · Cited by 2,949
Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies
Pabla, N., & Dong, Z. (2008) · Kidney International · doi:10.1038/sj.ki.5002786 · Cited by 1,918
Cisplatin Nephrotoxicity: A Review
Yao, X., Panichpisal, K., Kurtzman, N., & Nugent, K. (2007) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31812dfe1e · Cited by 1,251
Koepsell, H., Lips, K., & Volk, C. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9254-z · Cited by 988
Arany, I., & Safirstein, R. L. (2003) · Seminars in Nephrology · doi:10.1016/s0270-9295(03)00089-5 · Cited by 906
TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity
Ramesh, G., & Reeves, W. B. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15606 · Cited by 866
Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin
Go, R. S., & Adjei, A. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.409 · Cited by 697
Cui, Y., König, J., Buchholz, U., Spring, H., Leier, I., & Keppler, D. (1999) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23190-4 · Cited by 676
The SLC22 drug transporter family
Koepsell, H., & Endou, H. (2004) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/s00424-003-1089-9 · Cited by 525
The Role of Cellular Accumulation in Determining Sensitivity to Platinum-Based Chemotherapy
Hall, M. D., Okabe, M., Shen, D.-W., Liang, X.-J., & Gottesman, M. M. (2008) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.080907.180426 · Cited by 474
Lieberthal, W., Triaca, V., & Levine, J. (1996) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1996.270.4.f700 · Cited by 449
Cisplatin Nephrotoxicity Is Critically Mediated via the Human Organic Cation Transporter 2
Ciarimboli, G., Ludwig, T., Lang, D., Pavenstädt, H., Koepsell, H., Piechota, H.-J., Haier, J., Jaehde, U., Zisowsky, J., & Schlatter, E. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61234-5 · Cited by 448
Organic Cation Transporters Are Determinants of Oxaliplatin Cytotoxicity
Zhang, S., Lovejoy, K. S., Shima, J. E., Lagpacan, L. L., Shu, Y., Lapuk, A., Chen, Y., Komori, T., Gray, J. W., Chen, X., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0769 · Cited by 431
Molecular and Cellular Physiology of Renal Organic Cation and Anion Transport
Wright, S. H., & Dantzler, W. H. (2004) · Physiological Reviews · doi:10.1152/physrev.00040.2003 · Cited by 404
The apical conjugate efflux pump ABCC2 (MRP2)
Nies, A. T., & Keppler, D. (2007) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-006-0109-y · Cited by 398
Yonezawa, A., Masuda, S., Yokoo, S., Katsura, T., & Inui, K.-I. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.110346 · Cited by 344
Koepsell, H., Schmitt, B. M., & Gorboulev, V. (2003) · Reviews of Physiology, Biochemistry and Pharmacology · doi:10.1007/s10254-003-0017-x · Cited by 316
Sweet, D. H., Miller, D. S., Pritchard, J. B., Fujiwara, Y., Beier, D. R., & Nigam, S. K. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203803200 · Cited by 287
Pabla, N., Murphy, R. F., Liu, K., & Dong, Z. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.90545.2008 · Cited by 283
TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure
Ramesh, G., & Reeves, W. B. (2003) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00101.2003 · Cited by 282
Megyesi, J., Safirstein, R. L., & Price, P. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1497 · Cited by 272
Nephrotoxicity and Hydration Management for Cisplatin, Carboplatin, and Ormaplatin
Cornelison, T. L., & Reed, E. (1993) · Gynecologic Oncology · doi:10.1006/gyno.1993.1184 · Cited by 270
Genetic Variants of the Organic Cation Transporter 2 Influence the Disposition of Metformin
Song, I., Shin, H., Shim, E., Jung, I., Kim, W., Shon, J., & Shin, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.61 · Cited by 268
p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice
Ramesh, G., & Reeves, W. B. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00401.2004 · Cited by 267
Jonker, J. W., Wagenaar, E., van Eijl, S., & Schinkel, A. H. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.21.7902-7908.2003 · Cited by 265
Self-citationYokoo, S., Yonezawa, A., Masuda, S., Fukatsu, A., Katsura, T., & Inui, K.-I. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.03.004 · Cited by 250
Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition
Jedlitschky, G., Hoffmann, U., & Kroemer, H. K. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.3.351 · Cited by 238
Activation and involvement of p53 in cisplatin-induced nephrotoxicity
Wei, Q., Dong, G., Yang, T., Megyesi, J., Price, P. M., & Dong, Z. (2007) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00230.2007 · Cited by 232
Jonker, J. W., Wagenaar, E., Mol, C. A. A. M., Buitelaar, M., Koepsell, H., Smit, J. W., & Schinkel, A. H. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.16.5471-5477.2001 · Cited by 227
Self-citationROLE OF ORGANIC CATION TRANSPORTERS IN DRUG ABSORPTION AND ELIMINATION
Zhang, L., Brett, C. M., & Giacomini, K. M. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.431 · Cited by 202
Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function
Leabman, M. K., Huang, C. C., Kawamoto, M., Johns, S. J., Stryke, D., Ferrin, T. E., DeYoung, J., Taylor, T., Clark, A. G., Herskowitz, I., et al. (2002) · Pharmacogenetics · doi:10.1097/00008571-200207000-00007 · Cited by 191
Khamdang, S., Takeda, M., Noshiro, R., Narikawa, S., Enomoto, A., Anzai, N., Piyachaturawat, P., & Endou, H. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.037580 · Cited by 189
Yonezawa, A., Masuda, S., Nishihara, K., Yano, I., Katsura, T., & Inui, K.-I. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.09.020 · Cited by 180
Nephrotoxicity of platinum complexes is related to basolateral organic cation transport
Ludwig, T., Riethmüller, C., Gekle, M., Schwerdt, G., & Oberleithner, H. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00720.x · Cited by 179
Hinoshita, E., Uchiumi, T., Taguchi, K., Kinukawa, N., Tsuneyoshi, M., Maehara, Y., Sugimachi, K., & Kuwano, M. (2000) · PubMed · Cited by 179
Irinotecan-induced Diarrhea: Functional Significance of the Polymorphic ABCC2 Transporter Protein
de Jong, F. A., Scott-Horton, T. J., Kroetz, D. L., McLeod, H. L., Friberg, L. E., Mathijssen, R. H., Verweij, J., Marsh, S., & Sparreboom, A. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100019 · Cited by 171
Self-citationPharmacogenetic Pathway Analysis of Docetaxel Elimination
Baker, S., Verweij, J., Cusatis, G., van Schaik, R., Marsh, S., Orwick, S., Franke, R., Hu, S., Schuetz, E., Lamba, V, et al. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.95 · Cited by 170
Self-citationInteraction of Cisplatin with the Human Organic Cation Transporter 2
Filipski, K. K., Loos, W. J., Verweij, J., & Sparreboom, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4793 · Cited by 169
Self-citationCisplatin nephrotoxicity: insights into mechanism
Safirstein, R. L., Winston, J. A., Moel, D. I., DIKMAN, S. H., & Guttenplan, J. B. (1987) · International Journal of Andrology · doi:10.1111/j.1365-2605.1987.tb00200.x · Cited by 147
Characterization of Mice Lacking the Multidrug Resistance Protein Mrp2 (Abcc2)
Chu, X., Strauss, J. R., Mariano, M. A., Li, J., Newton, D. J., Cai, X., Wang, R. W., Yabut, J. A., Hartley, D. P., Evans, D. C., et al. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.098665 · Cited by 145
Saito, S., Iida, A., Sekine, A., Miura, Y., Ogawa, C., Kawauchi, S., Higuchi, S., & Nakamura, Y. (2002) · Journal of Human Genetics · doi:10.1007/s100380200018 · Cited by 135
Fujita, T., Urban, T., Leabman, M. K., et al. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20536 · Cited by 133
Body-Surface Area–Based Dosing Does Not Increase Accuracy of Predicting Cisplatin Exposure
de Jongh, F. E., Verweij, J., Loos, W. J., de Wit, R., de Jonge, M. J. A., Planting, A. S. T., Nooter, K., Stoter, G., & Sparreboom, A. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.17.3733 · Cited by 130
Self-citationProtection of renal cells from cisplatin toxicity by cell cycle inhibitors
Price, P. M., Safirstein, R. L., & Megyesi, J. K. (2004) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00192.2003 · Cited by 128
Hirouchi, M., Suzuki, H., Itoda, M., Ozawa, S., Sawada, J.-I., Ieiri, I., Ohtsubo, K., & Sugiyama, Y. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000026422.06207.33 · Cited by 110
Kang, H., Song, I., Shin, H. J., Kim, W., Lee, C., Shim, J.-C., Zhou, H., Lee, S. S., & Shin, J. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.013581 · Cited by 108
Shu, Y., Bello, C. L., Mangravite, L. M., Feng, B., & Giacomini, K. M. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29342-3 · Cited by 96
VanWert, A. L., Bailey, R. M., & Sweet, D. H. (2007) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00319.2007 · Cited by 91
Renal xenobiotic transporters are differentially expressed in mice following cisplatin treatment
Aleksunes, L. M., Augustine, L. M., Scheffer, G. L., Cherrington, N. J., & Manautou, J. E. (2008) · Toxicology · doi:10.1016/j.tox.2008.06.009 · Cited by 90
Endotoxin and cisplatin synergistically stimulate TNF-α production by renal epithelial cells
Ramesh, G., Kimball, S. R., Jefferson, L. S., & Reeves, W. B. (2006) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00277.2006 · Cited by 64
(2008) · doi:10.1158/1078-0432.ccr-08-1609 · Cited by 57
Renal toxicities of antineoplastic drugs and bone marrow transplantation.
Berns, J. S., & Ford, P. (1997) · PubMed · Cited by 39
Ma, J., Maliepaard, M., Kolker, H. J., Verweij, J., & Schellens, J. H. M. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050727 · Cited by 34
Loos, W. J., de Jongh, F. E., Sparreboom, A., de Wit, R., van Zomeren, D. M., Stoter, G., Nooter, K., & Verweij, J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0056 · Cited by 32
Self-citation
Cited by
Mechanisms of Cisplatin Nephrotoxicity
Miller, R. P., Tadagavadi, R. K., Ramesh, G., & Reeves, W. B. (2010) · Toxins · doi:10.3390/toxins2112490 · Cited by 1,622
A catalog of genetic loci associated with kidney function from analyses of a million individuals
Study, L. C., Wuttke, M., Program, V. A. M. V., Li, Y., Li, M., Sieber, K. B., Feitosa, M. F., Gorski, M., Tin, A., Wang, L., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0407-x · Cited by 846
Xenobiotic, Bile Acid, and Cholesterol Transporters: Function and Regulation
Klaassen, C. D., & Aleksunes, L. M. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002014 · Cited by 807
Drug-induced oxidative stress and toxicity
Deavall, D. G., Martin, E. A., Horner, J. M., & Roberts, R. (2012) · Journal of Toxicology · doi:10.1155/2012/645460 · Cited by 689
Cisplatin nephrotoxicity: a review of the literature
Manohar, S., & Leung, N. (2018) · Journal of Nephrology · doi:10.1007/s40620-017-0392-z · Cited by 636
Metadata
- Authors
- Filipski, K. K., Mathijssen, R. H., Mikkelsen, T. S., Schinkel, A. H., & Sparreboom, A.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2009-07-22
- Volume
- 86
- Issue
- 4
- Pages
- 396-402
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2096515859
- Cited by
- 399
- References
- 58
- FWCI
- 11.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.